Protein-loss of SWI/SNF-complex core subunits influences prognosis dependent on histological subtypes of intra- and extrahepatic cholangiocarcinoma

• Published in: Oncology letters Vol. 21; no. 5; p. 349
• Main Authors: Wagner, Britta Janina, Plum, Patrick Sven, Apel, Katharina, Scherer, Marie, Buchner, Denise, Brinkmann, Sebastian, Buettner, Reinhard, Stippel, Dirk, Quaas, Alexander, Drebber, Uta
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications 01.05.2021; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Analysis; Automation; Biomarkers; Cholangiocarcinoma; Chromatin; Cloning; DNA microarrays; Ethylenediaminetetraacetic acid; Health aspects; Medical prognosis; Medical research; Medicine, Experimental; Mortality; Mutation; Oncology; Patients; Proteins; Surgery; Surgical outcomes; Survival analysis; Germany; SWI/SNF-complex; small duct type intrahepatic cholangiocarcinoma; ARID1a; BRM; large duct type intrahepatic cholangiocarcinoma; PBRM-1; extrahepatic cholangiocarcinoma
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2021.12610

Cholangiocarcinoma (CCA) is an aggressive malignancy with a 5-year-survival rate of <10%, mainly due to diagnosis in advanced stages and limited therapeutic options in case of progressive disease. Recently, evidence has indicated that alterations in the SWI/SNF-complex (SWI/SNF) may have an important role in the tumorigenesis of CCA. SWI/SNF-related chromatin remodeling has been reported to be crucial for differentiation and tumor suppression, and loss-of-function mutations of SWI/SNF are present in 20% of human malignancies; however, at present, little is known about its relevance in CCA. In the present study, a cohort of 52 patients with the diagnosis of primary CCA was retrospectively collected. All patients underwent surgery with curative intent. Tissue microarray analysis was performed on each tumor for immunohistochemical loss-of-protein analysis of the SWI/SNF core subunits ARID1A, INI-1, BRG1, PBRM-1 and BRM, corresponding to the following CCA subtypes: Extrahepatic CCA (ECCA), small duct or large duct intrahepatic CCA (ICCA). Kaplan-Meier analysis was used to determine survival distribution and survival differences were evaluated by log-rank test. In total, 14 of 52 patients (~35%) exhibited protein-loss of any tested SWI/SNF core subunit. Notably, 17% of patients exhibited a loss of ARID1a; this was the protein loss with the highest frequency. Patients with small and large duct ICCA with protein-loss of any tested SWI/SNF subunit exhibited significantly worse survival compared with the wild-type cohort with proficient protein expression (P=0.013 and P=0.002), whereas no significant survival difference was detected for patients with ECCA. SWI/SNF and its core subunits may be considered promising predictive and therapeutic targets, and require further investigation in patients with CCA.